These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 36205855)

  • 1. Cardiomyocyte-specific overexpression of syndecan-4 in mice results in activation of calcineurin-NFAT signalling and exacerbated cardiac hypertrophy.
    Lunde IG; Aronsen JM; Melleby AO; Strand ME; Skogestad J; Bendiksen BA; Ahmed MS; Sjaastad I; Attramadal H; Carlson CR; Christensen G
    Mol Biol Rep; 2022 Dec; 49(12):11795-11809. PubMed ID: 36205855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Syndecan-4 is essential for development of concentric myocardial hypertrophy via stretch-induced activation of the calcineurin-NFAT pathway.
    Finsen AV; Lunde IG; Sjaastad I; Østli EK; Lyngra M; Jarstadmarken HO; Hasic A; Nygård S; Wilcox-Adelman SA; Goetinck PF; Lyberg T; Skrbic B; Florholmen G; Tønnessen T; Louch WE; Djurovic S; Carlson CR; Christensen G
    PLoS One; 2011; 6(12):e28302. PubMed ID: 22164265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Syndecan-4 signalling inhibits apoptosis and controls NFAT activity during myocardial damage and remodelling.
    Echtermeyer F; Harendza T; Hubrich S; Lorenz A; Herzog C; Mueller M; Schmitz M; Grund A; Larmann J; Stypmann J; Schieffer B; Lichtinghagen R; Hilfiker-Kleiner D; Wollert KC; Heineke J; Theilmeier G
    Cardiovasc Res; 2011 Oct; 92(1):123-31. PubMed ID: 21632883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cooperative Binding of ETS2 and NFAT Links Erk1/2 and Calcineurin Signaling in the Pathogenesis of Cardiac Hypertrophy.
    Luo Y; Jiang N; May HI; Luo X; Ferdous A; Schiattarella GG; Chen G; Li Q; Li C; Rothermel BA; Jiang D; Lavandero S; Gillette TG; Hill JA
    Circulation; 2021 Jul; 144(1):34-51. PubMed ID: 33821668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Syndecan-4 signaling via NFAT regulates extracellular matrix production and cardiac myofibroblast differentiation in response to mechanical stress.
    Herum KM; Lunde IG; Skrbic B; Florholmen G; Behmen D; Sjaastad I; Carlson CR; Gomez MF; Christensen G
    J Mol Cell Cardiol; 2013 Jan; 54():73-81. PubMed ID: 23178899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced expression of DYRK1A in cardiomyocytes inhibits acute NFAT activation but does not prevent hypertrophy in vivo.
    Grebe C; Klingebiel TM; Grau SP; Toischer K; Didié M; Jacobshagen C; Dullin C; Hasenfuss G; Seidler T
    Cardiovasc Res; 2011 Jun; 90(3):521-8. PubMed ID: 21273244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A gene therapeutic approach to inhibit calcium and integrin binding protein 1 ameliorates maladaptive remodelling in pressure overload.
    Grund A; Szaroszyk M; Döppner JK; Malek Mohammadi M; Kattih B; Korf-Klingebiel M; Gigina A; Scherr M; Kensah G; Jara-Avaca M; Gruh I; Martin U; Wollert KC; Gohla A; Katus HA; Müller OJ; Bauersachs J; Heineke J
    Cardiovasc Res; 2019 Jan; 115(1):71-82. PubMed ID: 29931050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiac anti-remodelling effect of aerobic training is associated with a reduction in the calcineurin/NFAT signalling pathway in heart failure mice.
    Oliveira RS; Ferreira JC; Gomes ER; Paixão NA; Rolim NP; Medeiros A; Guatimosim S; Brum PC
    J Physiol; 2009 Aug; 587(Pt 15):3899-910. PubMed ID: 19505981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decreased KCNE2 Expression Participates in the Development of Cardiac Hypertrophy by Regulation of Calcineurin-NFAT (Nuclear Factor of Activated T Cells) and Mitogen-Activated Protein Kinase Pathways.
    Liu W; Deng J; Ding W; Wang G; Shen Y; Zheng J; Zhang X; Luo Y; Lv C; Wang Y; Chen L; Yan D; Boudreau RL; Song LS; Liu J
    Circ Heart Fail; 2017 Jun; 10(6):. PubMed ID: 28611128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy.
    Wilkins BJ; Dai YS; Bueno OF; Parsons SA; Xu J; Plank DM; Jones F; Kimball TR; Molkentin JD
    Circ Res; 2004 Jan; 94(1):110-8. PubMed ID: 14656927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cross-talk between calcineurin/NFAT and Jak/STAT signalling induces cardioprotective alphaB-crystallin gene expression in response to hypertrophic stimuli.
    Manukyan I; Galatioto J; Mascareno E; Bhaduri S; Siddiqui MA
    J Cell Mol Med; 2010 Jun; 14(6B):1707-16. PubMed ID: 19538478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PICOT attenuates cardiac hypertrophy by disrupting calcineurin-NFAT signaling.
    Jeong D; Kim JM; Cha H; Oh JG; Park J; Yun SH; Ju ES; Jeon ES; Hajjar RJ; Park WJ
    Circ Res; 2008 Mar; 102(6):711-9. PubMed ID: 18258855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted disruption of Hspa4 gene leads to cardiac hypertrophy and fibrosis.
    Mohamed BA; Barakat AZ; Zimmermann WH; Bittner RE; Mühlfeld C; Hünlich M; Engel W; Maier LS; Adham IM
    J Mol Cell Cardiol; 2012 Oct; 53(4):459-68. PubMed ID: 22884543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polydatin attenuates cardiac hypertrophy through modulation of cardiac Ca2+ handling and calcineurin-NFAT signaling pathway.
    Ding W; Dong M; Deng J; Yan D; Liu Y; Xu T; Liu J
    Am J Physiol Heart Circ Physiol; 2014 Sep; 307(5):H792-802. PubMed ID: 25015961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TRPC4α and TRPC4β Similarly Affect Neonatal Cardiomyocyte Survival during Chronic GPCR Stimulation.
    Kirschmer N; Bandleon S; von Ehrlich-Treuenstätt V; Hartmann S; Schaaf A; Lamprecht AK; Miranda-Laferte E; Langsenlehner T; Ritter O; Eder P
    PLoS One; 2016; 11(12):e0168446. PubMed ID: 27992507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Ca(v)3.2 T-type Ca(2+) channel is required for pressure overload-induced cardiac hypertrophy in mice.
    Chiang CS; Huang CH; Chieng H; Chang YT; Chang D; Chen JJ; Chen YC; Chen YH; Shin HS; Campbell KP; Chen CC
    Circ Res; 2009 Feb; 104(4):522-30. PubMed ID: 19122177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estrogen attenuates left ventricular and cardiomyocyte hypertrophy by an estrogen receptor-dependent pathway that increases calcineurin degradation.
    Donaldson C; Eder S; Baker C; Aronovitz MJ; Weiss AD; Hall-Porter M; Wang F; Ackerman A; Karas RH; Molkentin JD; Patten RD
    Circ Res; 2009 Jan; 104(2):265-75, 11p following 275. PubMed ID: 19074476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Muscle-specific RING finger 1 negatively regulates pathological cardiac hypertrophy through downregulation of calcineurin A.
    Maejima Y; Usui S; Zhai P; Takamura M; Kaneko S; Zablocki D; Yokota M; Isobe M; Sadoshima J
    Circ Heart Fail; 2014 May; 7(3):479-90. PubMed ID: 24526353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Syndecan-4 is a key determinant of collagen cross-linking and passive myocardial stiffness in the pressure-overloaded heart.
    Herum KM; Lunde IG; Skrbic B; Louch WE; Hasic A; Boye S; Unger A; Brorson SH; Sjaastad I; Tønnessen T; Linke WA; Gomez MF; Christensen G
    Cardiovasc Res; 2015 May; 106(2):217-26. PubMed ID: 25587045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overexpression of prostaglandin EP3 receptors activates calcineurin and promotes hypertrophy in the murine heart.
    Meyer-Kirchrath J; Martin M; Schooss C; Jacoby C; Flögel U; Marzoll A; Fischer JW; Schrader J; Schrör K; Hohlfeld T
    Cardiovasc Res; 2009 Feb; 81(2):310-8. PubMed ID: 19019835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.